Clinical Ink’s Chief Innovation Officer, Joan Severson, joined a group of panelists on The Real Chemistry podcast during this year’s SXSW to provide insight into how the use of innovative data sources for clinical trial recruitment has become increasingly important in recent years.
“Part of the challenge with clinical trials is that from the time you file a patent on a molecule, you have 20 years to recoup the money you’ll spend on developing that molecule into actual drug therapy. So every day you cut down is an opportunity to be able to continue to recoup the money that you spent. Technology has become a very important piece of how we can continue to have clinical trials go forward…”
Joan discusses how adopting technology in clinical trials can expedite the trial process, allowing sponsors to more quickly recover their investments. Technology is transforming the clinical research landscape by streamlining regulatory and compliance processes, study design, monitoring, data management, and retention of participants. Even before the start of the trials, technology through online social platforms can be used to effectively identify the right candidates for a study in the planning and recruitment stages of the trial process.
“AI and machine learning are going to have a tremendous impact on all these data streams that are coming together, and how they’re going to become meaningful information and not just data.”
Combining machine learning algorithms and predictive modeling to analyze data helps to identify patient populations that are likely to be interested in the study and meet eligibility criteria. To maximize the effectiveness of these innovative data sources for clinical trial recruitment, however, it is important to use a targeted approach that identifies the right candidates for the study. This can be achieved by ensuring that the recruitment messaging is clear, culturally sensitive, engaging, and resonates with the target audience.
“These devices are able to collect data that was never available, even to personal physicians, in terms of the frequency and the quality of the data that we’re able to capture. So I think that sensors and wearables that we’re wearing every day now will become a part of how we look at clinical care, not just clinical trials.”
Joan also delves into how consumer wearables are transforming clinical trials by providing a wealth of real-time, objective data on patients’ health and behavior. Additionally, wearables help reduce patient burden by allowing patients to easily participate in a clinical trial from their homes. This encourages increased patient engagement in trials by providing them with a sense of ownership over their data and allowing them to track their progress, leading to improved compliance and retention. Quality data is captured more frequently which, in conjunction with patient-reported outcomes on mobile apps, give insight to patient health and behavior during the trial to provide a more complete picture of the patient’s experience.
Listen to The Real Chemistry podcast to hear Joan Severson, Chief Innovation Officer, Clinical ink, and other panelists Bryan J. Hansen, Ph.D., Maimah Karmo, and Aaron Strout as they shed light on the challenges of clinical trials and the importance of patient involvement.
Talk to one of our Clinical ink experts to learn how our technology can help with your trial success.
